FT895

FT895 is a **highly selective small molecule inhibitor of histone deacetylase 11 (HDAC11)**, showing an IC50 of 3 nM for HDAC11 and >1000-fold selectivity against other HDAC isoforms[1][3][9]. It acts as an **epigenetic modulator** and displays antifungal, antitumor, and antiviral activity[1][4][5][8]. Preclinical studies show FT895 restricts enterovirus 71 (EV71) replication in vitro and in vivo and potentiates the tumoricidal effect of other agents such as cordycepin against malignant peripheral nerve sheath tumors (MPNST)[4][5][8]. In animal models, FT895 also promotes thermogenesis and affects metabolic regulation by inducing UCP1 expression in adipose tissue[2]. FT895 induces mitochondrial dysfunction, increased reactive oxygen species production, and modulation of Hippo/YAP pathway activity in cancer models[6][8]. The compound is not orally bioavailable and contains a hydroxamic acid warhead[2]. FT895 is mainly used in research settings for cancer, infectious disease, and metabolic disease studies.

Brand names

FT895FT-895FT 895

Other names

FT895FT-895FT 895